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Background: Factor XIIIa (FXIIIa) cross-links fibrin strands and is essential for the generation of shear resistant platelet fibrin clot. FXIIIa plasma 
concentrations affect maximal clot strength (TEG-G) by thrombelastography (TEG). TEG-G is increased in patients with coronary artery disease (CAD) 
presenting with ACS and has been linked to increased risk of ischemic events after PCI. It has been estimated that up to 50% of circulating FXIIIa 
may be stored in platelets and released upon platelet activation. The release of FXIIIa from platelets upon stimulation with ADP and its contribution 
to plasma TEG parameters in patients treated with clopidogrel has not been previously examined.
methods: Samples from 96 patients with established CAD treated with aspirin and clopidogrel were examined. Platelet aggregation was performed 
using light transmittance aggregometry (LTA) using platelet rich plasma (PRP) and platelet poor plasma (PPP) as reference and ADP 5µM as agonist. 
Kaolin activated TEG was performed in citrate PPP. PRP after aggregation was centrifuged and plasma supernatant (PSN) collected. FXIIIa ELISA was 
performed in PPP and PSN.
results: Platelet aggregation after stimulation with ADP 5µM resulted in 24% additional FXIIIa release in PSN as compared to PPP (99.3 ± 27 vs. 
80.3 ± 24 %, p<0.0001). FXIIIa concentration in PSN correlated well with TEG-G (r=0.48, p<0.0001), but not in PPP (r=0.15, p=0.14). Increasing 
quartiles of platelet derived FXIIIa were associated with incrementally higher TEG-G (p=0.012). Maximal clot strength was significantly higher in the 
highest quartile as compared to lowest quartile of platelet derived FXIIIa (TEG-G: 3746±396 vs. 2707±148 dyn/cm2; p=0.017).
conclusions: Platelets treated with aspirin and clopidogrel release a significant amount of FXIIIa upon aggregation by ADP. Platelet derived FXIIIa 
may contribute to fibrin stabilization and maximal clot strength in patients with coronary artery disease.
